sorafenib has been researched along with 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine) | Trials (7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine) | Recent Studies (post-2010) (7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 9 | 0 | 3 |
Protein | Taxonomy | sorafenib (IC50) | 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine (IC50) |
---|---|---|---|
Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.65 | |
[Tau protein] kinase | Sus scrofa (pig) | 0.65 | |
G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.15 | |
G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.4 | |
Cyclin-dependent kinase 1 | Saccharomyces cerevisiae S288C | 2.5 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.15 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.15 | |
G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.3333 | |
Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.3333 | |
Cyclin-A2 | Homo sapiens (human) | 0.12 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.4 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.26 | |
Mitogen-activated protein kinase 8 | Homo sapiens (human) | 3.3 | |
Mitogen-activated protein kinase 9 | Homo sapiens (human) | 3.3 | |
Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.8239 | |
Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.9326 | |
Mitogen-activated protein kinase 10 | Homo sapiens (human) | 3.3 | |
Cyclin-A1 | Homo sapiens (human) | 0.12 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.245 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.245 | |
G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.15 | |
Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.3333 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z | 1 |
1 review(s) available for sorafenib and 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine
Article | Year |
---|---|
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors | 2019 |